Literature DB >> 23720723

Replication fitness of multiple nonnucleoside reverse transcriptase-resistant HIV-1 variants in the presence of etravirine measured by 454 deep sequencing.

Chanson J Brumme1, Kelly D Huber, Winnie Dong, Art F Y Poon, P Richard Harrigan, Nicolas Sluis-Cremer.   

Abstract

We applied an efficient method to characterize the relative fitness levels of multiple nonnucleoside reverse transcriptase (NNRTI)-resistant HIV-1 variants by simultaneous competitive culture and 454 deep sequencing. Using this method, we show that the Y181V mutation in the HIV-1 reverse transcriptase in particular confers a clear selective advantage to the virus over 14 other NNRTI resistance mutations in the presence of etravirine in vitro.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23720723      PMCID： PMC3719830          DOI： 10.1128/JVI.00335-13

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  5 in total

1.  TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1.

Authors:  Koen Andries; Hilde Azijn; Theo Thielemans; Donald Ludovici; Michael Kukla; Jan Heeres; Paul Janssen; Bart De Corte; Johan Vingerhoets; Rudi Pauwels; Marie-Pierre de Béthune
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

2.  A recombinant retroviral system for rapid in vivo analysis of human immunodeficiency virus type 1 susceptibility to reverse transcriptase inhibitors.

Authors:  C Shi; J W Mellors
Journal:  Antimicrob Agents Chemother       Date:  1997-12       Impact factor: 5.191

3.  Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies.

Authors:  Johan Vingerhoets; Lotke Tambuyzer; Hilde Azijn; Annemie Hoogstoel; Steven Nijs; Monika Peeters; Marie-Pierre de Béthune; Goedele De Smedt; Brian Woodfall; Gastón Picchio
Journal:  AIDS       Date:  2010-02-20       Impact factor: 4.177

4.  Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial.

Authors:  Adriano Lazzarin; Thomas Campbell; Bonaventura Clotet; Margaret Johnson; Christine Katlama; Arend Moll; William Towner; Benoit Trottier; Monika Peeters; Johan Vingerhoets; Goedele de Smedt; Benny Baeten; Greet Beets; Rekha Sinha; Brian Woodfall
Journal:  Lancet       Date:  2007-07-07       Impact factor: 79.321

Review 5.  Clinical significance of human immunodeficiency virus type 1 replication fitness.

Authors:  Carrie Dykes; Lisa M Demeter
Journal:  Clin Microbiol Rev       Date:  2007-10       Impact factor: 26.132
  5 in total
  5 in total

1.  Different Effects of Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations on Cytotoxic T Lymphocyte Recognition between HIV-1 Subtype B and Subtype A/E Infections.

Authors:  Nozomi Kuse; Mohammad Arif Rahman; Hayato Murakoshi; Giang Van Tran; Takayuki Chikata; Madoka Koyanagi; Kinh Van Nguyen; Hiroyuki Gatanaga; Shinichi Oka; Masafumi Takiguchi
Journal:  J Virol       Date:  2015-05-13       Impact factor: 5.103

2.  Competitive fitness assays indicate that the E138A substitution in HIV-1 reverse transcriptase decreases in vitro susceptibility to emtricitabine.

Authors:  Nicolas Sluis-Cremer; Kelly D Huber; Chanson J Brumme; P Richard Harrigan
Journal:  Antimicrob Agents Chemother       Date:  2014-01-13       Impact factor: 5.191

3.  Nonnucleoside Reverse Transcriptase Inhibitor Hypersusceptibility and Resistance by Mutation of Residue 181 in HIV-1 Reverse Transcriptase.

Authors:  John P Barnard; Kelly D Huber; Nicolas Sluis-Cremer
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

Review 4.  Deep sequencing: becoming a critical tool in clinical virology.

Authors:  Miguel E Quiñones-Mateu; Santiago Avila; Gustavo Reyes-Teran; Miguel A Martinez
Journal:  J Clin Virol       Date:  2014-06-24       Impact factor: 3.168

5.  High-Resolution Sequencing of Viral Populations during Early Simian Immunodeficiency Virus Infection Reveals Evolutionary Strategies for Rapid Escape from Emerging Env-Specific Antibody Responses.

Authors:  Sergio Ita; Alison K Hill; Evan C Lam; Fay J Dufort; Xiao Yang; Ruchi Newman; Sivan Leviyang; Ismael B Fofana; Welkin E Johnson
Journal:  J Virol       Date:  2018-03-14       Impact factor: 5.103
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.